Enfortumab vedotin for cisplatin-ineligible urothelial cancer

Lancet Oncol. 2021 Jun;22(6):748-749. doi: 10.1016/S1470-2045(21)00142-X. Epub 2021 May 12.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Carcinoma, Transitional Cell* / drug therapy
  • Cisplatin* / adverse effects
  • Humans
  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor

Substances

  • Antibodies, Monoclonal
  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor
  • enfortumab vedotin
  • Cisplatin